SCHEMBL4345119

SCHEMBL4345119

CCC1CN(C(=O)c2ccc(F)c(F)c2Nc2ccc(I)cc2F)C1

nearest known ligand 0.77

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 20/20 0.77
MAP2K2 P36507 19/20 0.77
CHRM2 P08172 1/20 0.57
CHRM1 P11229 1/20 0.57
BRAF P15056 1/20 0.57
DRD1 P21728 1/20 0.57
TBXA2R P21731 1/20 0.57
SLC6A2 P23975 1/20 0.57
SLC6A4 P31645 1/20 0.57
ADRA1A P35348 1/20 0.57
OPRM1 P35372 1/20 0.57
DRD3 P35462 1/20 0.57
ACTR3 P61158 1/20 0.57
SLC6A3 Q01959 1/20 0.57
KCNH2 Q12809 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29413480 0.91 MAP2K2 (0.78) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL189491 0.91 MAP2K2 (0.78) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL3109800 0.90 MAP2K1 (0.77) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL3828613 0.89 MAP2K2 (0.70) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL1488676 0.89 MAP2K1 (0.73) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL30221025 0.89 MAP2K1 (0.73) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL4997116 0.88 MAP2K1 (0.82) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL30221026 0.88 MAP2K1 (0.74) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL1488284 0.88 MAP2K1 (0.74) MAP2K1MAP2K2CHRM2CHRM1BRAF
SCHEMBL29413648 0.87 MAP2K1 (0.70) MAP2K1MAP2K2CHRM2CHRM1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2056829-A2 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER Exelixis, Inc. (US) 2009-05-13 EP claimed
WO-2008021389-A2 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER EXELIXIS, INC. (US) 2008-02-21 WO claimed